Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development.

Autor: Gautam N; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Ramamoorthi G; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Champion N; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Han HS; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Czerniecki BJ; Clinical Science & Immunology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: brian.czerniecki@moffitt.org.
Jazyk: angličtina
Zdroj: Molecular aspects of medicine [Mol Aspects Med] 2024 Feb; Vol. 95, pp. 101239. Date of Electronic Publication: 2023 Dec 26.
DOI: 10.1016/j.mam.2023.101239
Abstrakt: Breast cancer is a heterogeneous disease and is the most prevalent cancer in women. According to the U.S breast cancer statistics, about 1 in every 8 women develop an invasive form of breast cancer during their lifetime. Immunotherapy has been a significant advancement in the treatment of cancer with multiple studies reporting favourable patient outcomes by modulating the immune response to cancer cells. Here, we review the significance of dendritic cell vaccines in treating breast cancer patients. We discuss the involvement of dendritic cells and oncodrivers in breast tumorigenesis, highlighting the rationale for targeting oncodrivers and neoantigens using dendritic cell vaccine therapy. We review different dendritic cell subsets and maturation states previously used to develop vaccines and suggest the use of DC vaccines for breast cancer prevention. Further, we highlight that the intratumoral delivery of type 1 dendritic cell vaccines in breast cancer patients activates tumor antigen-specific CD4 + T helper cell type 1 (Th1) cells, promoting an anti-tumorigenic immune response while concurrently blocking pro-tumorigenic responses. In summary, this review provides an overview of the current state of dendritic cell vaccines in breast cancer highlighting the challenges and considerations necessary for an efficient dendritic cell vaccine design in interrupting breast cancer development.
Competing Interests: Declaration of competing interest BJC has a patent application filed for intellectual property on a human version of DC1. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: